Clinical trial of repeated intraperitoneal administration of GAIA-102 in patients with microsatellite stable (MSS) advanced gastrointestinal cancer (gastric cancer/pancreatic cancer) accompanied by malignant ascites (Phase I/II investigator-initiated clinical trial)
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs GAIA 102 (Primary)
- Indications Gastric cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2025 New Source Identified and Integrated (jRCT2073220017: Japan Registry of Clinical Trials )
- 15 Jan 2025 New trial record